AEterna Zentaris Inc. (USA) (NASDAQ: AEZS), a specialty biopharmaceutical company engaged in developing and commercializing novel treatments in oncology, endocrinology and women’s health, reported …
H.C.
Canaccord Genuity analyst Neil Maruoka came out with a research note on AEterna Zentaris Inc. (USA) (NASDAQ:AEZS), reducing the price target to $0.
Maxim Group's healthcare analyst Jason Kolbert came out with a research note on AEterna Zentaris Inc. (USA) (NASDAQ:AEZS), after the company reported its fourth-quarter financial results and provided a corporate …